Summary:
Abbott has unveiled the arrival of its spinal cord stimulation system, Eterna, in Spain. Representing the world’s smallest implantable and rechargeable neurostimulation system, Eterna has gained CE marking for chronic pain treatment. Leveraging Abbott’s patented BurstDR stimulation, it stands as the sole spinal stimulation therapy with a waveform attaining the highest level of clinical evidence (1A). It has demonstrated a remarkable 23% reduction in chronic pain compared to traditional neuromodulation forms.
Eterna’s development stems from extensive patient, physician, and caregiver studies aimed at understanding unmet needs in chronic pain management. Patients sought a smaller implant for enhanced comfort and reduced device charging frequency. Addressing these concerns, Abbott engineered Eterna for only five annual recharges under nominal usage, optimizing patient experience.
The device’s key features include its status as the smallest implantable, rechargeable spinal stimulator on the market, designed for daily patient comfort. It uniquely incorporates BurstDR waveforms, mimicking natural physiological stimulation patterns found in the brain, delivering superior pain relief compared to other devices. As a result, 87% of patients prefer BurstDR stimulation over traditional tonic stimulation.
Moreover, Eterna employs Abbott’s TotalScan MRI technology, enabling full-body magnetic resonance imaging. This capability is critical for chronic pain patients requiring comprehensive diagnostic accessibility for improved healthcare.
Eterna can sync with patients’ or caregivers’ iPhones, with Abbott’s patient-oriented mobile application providing real-time updates on battery life, charging status, and therapy settings.
«Clincally proven BurstDR stimulation reduces pain, enhances individuals’ ability to perform daily activities, and diminishes emotional suffering associated with pain,» explains Dr. Agustín Mendiola, head of the pain unit at Puerta de Hierro Majadahonda Hospital. «Until now, Spain lacked such a small, rechargeable device requiring only five annual charges. Undoubtedly, this marks a significant advancement enabling chronic pain patients to attain a better quality of life,» adds Dr. Jose Cid Calzada, coordinator of the Pain Unit at the University Hospital Complex of Toledo.
These innovations cater to over 12 million chronic pain sufferers in Spain. Neurostimulation has been recommended by healthcare professionals for over 50 years to help patients manage chronic pain and enhance their quality of life. Devices used for neurostimulation comprise thin wires placed between the spinal cord and vertebrae and a small implant under the skin in the lower back, aiding in intercepting pain signals before they reach the brain.
Article written by PMFarma
10/04/2024
Source:
PMFarma
https://www.pmfarma.com/noticias/56351-abbott-lanza-en-espaya-el-sistema-de-neuroestimulaciyin-implantable-y-recargable-myos-pequeyo-del-mercado-para-el-tratamiento-del-dolor-cr.html